34 results about "Staphylococcus lactis" patented technology

The application discloses a Vibrio harveyi oral vaccine and a preparation method and application thereof. The application uses a lactococcus lactis NZ9000 expression system, modifies transformation parameters, effectively expresses Vibrio harveyi OmpU protein, constructs a lactococcus lactis (NZ9000) engineering bacterium expressing Vibrio harveyi outer membrane protein (OmpU), develops an oral vaccine against Vibrio harveyi infection, aims to reduce the infection of economic animals in seawater aquaculture by oral administration, provides a new scheme for dealing with the harm of Vibrio harveyi infection and antibiotic resistance and the like, promotes the breeding of fry and fingerlings, and promotes the development of biological agriculture and related industries. The strategy is expected to overcome the problems of traditional injection vaccines, such as inconvenient operation and great stress, and can provide a new technical scheme for reducing the dependence of the aquaculture industry on antibiotics and promoting the establishment of a green and healthy breeding mode.

A starter culture for the fermentation of a plant-based milk alternative is provided, which is particularly suitable for the production of a plant-based yogurt alternative. The starter culture comprises lactic acid bacteria isolated from legume plant material, especially pea plant material. Preferably, the starter culture comprises lactic acid bacteria of the species Lactobacillus rhamnosus and / or Lactococcus lactis subsp. cremoris.

This invention aims to address the technical bottlenecks of existing milk curd products, such as weak functional activity, unclear process parameters, and unstable flavor and quality. It utilizes *Pediococcus pentosaceus* HM4, *Streptococcus thermophilus* HM6, *Lactococcus lactis* JY4, and *Lactobacillus plantarum* NC1, employing these four strains in an optimal ratio as a compound fermentation agent to achieve synergistic effects. Using milk and goji berries as raw materials, the fermentation process of milk curds and goji berry milk curds was systematically optimized through single-factor experiments, Plackett-Burman experiments, and response surface methodology. The physicochemical indicators and flavor characteristics of the products under different process conditions were analyzed. The obtained milk curds achieved a DPPH free radical scavenging rate of 91.38%–94.15%, providing technical support for the high-value utilization of milk curds and enriching the variety of functional dairy products.

The application discloses a kind of complex fermentation inoculant for improving equol production, fermentation liquor and application thereof, belong to microbial fermentation technical field.The complex fermentation inoculant of the application, streptococcus thermophilus BLCC2-0025 and lactococcus lactis MP1001 have high β-glucosidase activity, and low activity glycoside form is converted into high activity daidzein;Salivary lactobacillus LS1101 and lactobacillus gregius 0010 have the activity of further converting daidzein into equol;Four strains of bacteria are used in combination, which can synergistically improve the content of equol.The fermentation liquor prepared by fermenting pueraria extract with the complex fermentation inoculant of the application can target regulate intestine-ovary axis, significantly improve the reproductive function of POF mice, relieve ovarian oxidative stress and accurately regulate intestinal flora balance, providing a safe and effective preparation and application scheme for non-hormone intervention of premature ovarian failure.

This invention discloses a *Lactococcus faecium* strain, YS-IM01. This strain can efficiently hydrolyze sheep colostrum proteins and specifically release a large amount of leucine. This invention also provides a polypeptide composition comprising multiple active peptides with potential for muscle synthesis, immunomodulation, and antioxidant activity. This invention further provides a fermented sheep colostrum product obtained by fermenting sheep colostrum with the aforementioned *Lactococcus faecium*. This invention also provides a method for preparing the fermented sheep colostrum product, comprising steps including fermentation, low-temperature vacuum concentration, and vacuum freeze-drying. Simultaneously, this invention also provides a method for preparing a drug using *Lactococcus faecium* and the polypeptide composition to prevent and / or improve age-related muscle loss.

The present invention relates to the strain Lactococcus lactis subsp. lactis CECT 31096, to its cellular components, metabolites, and secreted molecules, and to compositions comprising the above products, as well as to their uses as a medicament, preferably for the prevention and / or reduction of hypertension, or as a food composition or nutraceutical.

The application relates to the field of food biotechnology, and discloses a low-salt bean paste production process based on segmented temperature control fermentation, which is made of fava bean koji, water, edible salt, sodium hexametaphosphate, lactococcus lactis nisin, edible alcohol, granulated coarse granular calcium carbonate and glucono-delta-lactone. The production process comprises the following steps: constructing a composite matrix, and first performing buffer-type medium-temperature enzymolysis; then adding a glucono-delta-lactone aqueous solution in a flow manner, utilizing the stoichiometric coupling reaction of the glucono-delta-lactone aqueous solution and the granulated coarse granular calcium carbonate to generate carbon dioxide in situ to construct a micropore structure and regulate the pH value of the system; and finally, connecting a Zygosaccharomyces rouxii to perform low-temperature aroma-producing after-ripening. Through the synergistic effect of the components, the application effectively solves technical problems in the low-salt fermentation process, such as low protein solubility, easy compaction of the matrix and breeding of miscellaneous bacteria, and improves the amino acid nitrogen content and protein hydrolysis rate of the finished product.

Provided are methods for preventing or treating a chronic pain in a subject that includes administering an effective amount of a composition of Lactococcus lactis DSM 27109 to the subject.

This invention belongs to the field of bioengineering technology, specifically relating to a gene for efficiently expressing thymosin α1 (Tα1), recombinant lactic acid bacteria, and their applications. This invention provides a Tα1 encoding gene specifically optimized for *Lactococcus lactis* NZ9000, which significantly improves expression efficiency in the host through full-sequence codon adaptation. This gene was cloned into the vector pNZ8148-M, constructing the recombinant expression plasmid NZ9000 / pNZ8148-M. usp45 + T α1 The strain was successfully transformed into the host bacterium NZ9000, yielding recombinant lactic acid bacteria NZ9000 / pNZ8148-M. usp45 + Tα1 This recombinant strain can efficiently secrete the Tα1 fusion protein USP under Nisin induction. 45 +Tα1, the protein is digested in vitro by enterokinase to release active Tα1. The Tα1 produced by the method of this invention has high yield, high purity, high biological activity and excellent safety, providing a new technical platform for the low-cost, large-scale and safe production of Tα1.

This invention discloses a walnut oil-based yogurt with a milk skin and its preparation method, belonging to the field of dairy product technology. The walnut oil-based yogurt contains the following ingredients in parts by weight: 100 parts fresh milk, 3-7 parts walnut oil, 0.5-1.5 parts enzymatically hydrolyzed lecithin, and may also contain 4-8 parts protein powder, 6-10 parts cheese powder, 4-8 parts egg yolk powder, and 5-7 parts white sugar. The preparation method includes: heating the fresh milk and adding protein powder, cheese powder, and other ingredients; heating again and adding the remaining white sugar; emulsifying the walnut oil and lecithin at 55-65℃; homogenizing and sterilizing; cooling to 40-45℃ and inoculating with *Lactobacillus casei* and *Lactococcus lactis* subsp. *lactococcus*; fermenting at 30-35℃ for 10-14 hours, and then refrigerating at 2-6℃ for 16-24 hours to form a milk skin layer. The yogurt prepared by this invention has a unique milk skin layer, a rich taste, and high nutritional value.

The invention relates to the technical field of synthetic biology and immunotherapy, in particular to an immune gene combination fragment responding to a tumor microenvironment, a recombinant plasmid, probiotics and application of the immune gene combination fragment, the recombinant plasmid and the probiotics. The preparation method comprises the following steps: selecting phytobacterium plantarum, casei casei, casei paracasei, streptococcus thermophilus and lactococcus lactis as a probiotic chassis, further designing and assembling an immune gene combination fragment of immune checkpoint inhibitors (PD-L1 and CTLA-4), and uploading the immune gene combination fragment to the bacterial strain to construct customized probiotics, so as to prepare the immune checkpoint inhibitors (PD-L1 and CTLA-4). The in-vitro expression condition is researched; it is found that in a mouse tumor model, the customized probiotics can release PD-L1 and CTLA-4 nano antibodies at the tumor site, the tumor microenvironment is reversed, the immune system is mobilized, and the anti-tumor effect is enhanced. The research is expected to provide a safe and efficient anti-tumor strategy for tumor treatment, and new hope is brought to tumor patients.

The application belongs to the technical field of biological fermentation, and discloses a method for efficiently preparing earthworm functional liquid by using earthworm intestinal endogenous probiotics and enzymes and the earthworm functional liquid. The method comprises the following steps: step 1: activating and expanding B. velezensis XY1, P. megaspora and Lactococcus lactis respectively to obtain B. velezensis XY1 bacterial liquid, P. megaspora bacterial liquid and Lactococcus lactis bacterial liquid; and step 2: inoculating the B. velezensis XY1 bacterial liquid, the P. megaspora bacterial liquid, the Lactococcus lactis bacterial liquid and a compound enzyme into earthworm slurry to obtain the earthworm functional liquid. The B. velezensis XY1, the P. megaspora, the Lactococcus lactis and the compound enzyme are used for synergistic fermentation to obtain the earthworm functional liquid, the content of total amino acids and small peptides is significantly improved, and the effect of the earthworm functional liquid can be further improved.

This invention discloses a recombinant lactic acid bacteria expressing a truncated avian adenovirus Hexon protein, its construction method, and its applications, belonging to the field of biomedical technology. This invention is the first to construct recombinant lactic acid bacteria strains pNZ8149-FAdV4ΔHexon / NZ3900 and pNZ8149-FAdV8bΔHexon / NZ3900 expressing the truncated avian adenovirus Hexon protein. SDS-PAGE and Western blotting analyses showed that the exogenous genes FADV4-ΔHexon and FADV-8bΔHexon were successfully expressed in *Lactococcus lactis* and exhibited reactivity. Oral immunization of one-day-old chicks showed that oral administration of the recombinant lactic acid bacteria induced humoral and cellular immunity, as well as local mucosal immunity. The results indicate that the recombinant constitutive lactic acid bacteria prepared in this invention can enhance the immunity of chicks.

The present invention relates to a strain of Lactococcus lactis or a cell fraction thereof for use in the prevention and / or treatment of visceral pain.

The present application discloses a lactic acid pediococcus SWU-HX39 with the function of reducing uric acid, and the classification name is lactic acid pediococcus (Pediococcus acidilactici) Pediococcus acidilactici ), which is preserved in the China General Microbiological Culture Collection Center, with the preservation number of CGMCC No.33055, the preservation date of December 13, 2024, and the preservation address of No.3, Xili, Beichen West Road, Chaoyang District, Beijing. The lactic acid pediococcus SWU-HX39 can relieve the kidney damage caused by high uric acid, reduce the synthesis of uric acid, lower the concentration of uric acid in blood, improve the excretion of uric acid in the body, reduce the reabsorption of uric acid in the body, and achieve the effect of reducing uric acid. In addition, SWU-HX39 can reduce the expression of LPS and the expression of inflammatory factors IL-1beta, IL-6 and TNF alpha. That is, it has the functions of anti-inflammation and relieving liver inflammation, and can also increase the content of SCFAs in the body of patients with high uric acid, especially propionic acid, so as to reduce the uric acid level and improve the abnormal uric acid content.

The present invention relates to novel lactic acid bacteria, Lactococcus lactis P32 (KCCM13222P), Bifidobacterium bifidum P45 (KCCM13223P), or a mixture thereof, and uses thereof. Strains and a mixture thereof, according to the present invention, can be effectively used in the prevention or treatment of an inflammatory disease, osteoporosis, depressive disorder, or anxiety disorder.

The application discloses a lactic acid bacteria and application thereof in straw-based feed protein, and belongs to the technical field of microorganisms. The application screens out bacillus pumilus and lactococcus lactis which can efficiently utilize straw. It is verified through experiments that after the bacillus pumilus and the lactococcus lactis are cultured in a fermentation liquor with wheat straw as the only carbon source for 5-7 days, the crude protein content is increased to 28.1% after fermentation, and the straw degradation rate is more than 88%, so that efficient conversion of the straw into high-quality feed protein is realized. Therefore, through construction of specific functional flora, optimization of a medium formula and a fermentation process, the application successfully realizes one-step efficient degradation of the straw and production of high-quality single-cell protein, and has the outstanding advantages of high degradation efficiency, high protein yield, stable colony, low cost and easy industrialization.

Disclosed herein is an oral fish vaccine comprising a recombinant cell comprising virus-like particles, wherein the recombinant cell is intact, inactivated, and does not exhibit antibiotic resistance. In one preferred embodiment, the inactivation is performed using sodium hypochlorite. In another preferred embodiment, the recombinant cell is Escherichia coli (E. coli) or Lactococcus lactis (L lactis). In a further preferred embodiment, the virus-like particles comprise nervous necrosis virus capsid proteins and the vaccine is used in treating or preventing viral nervous necrosis.

The application discloses a recombinant Lactococcus lactis engineering bacterium expressing reformed Exendin-4 and a construction method and application thereof. The engineering bacterium is obtained by introducing a recombinant food-grade plasmid pNZ8149-UEm-His into Lactococcus lactis NZ3900, and the genotype is NZ3900 / pNZ8149-UEm-His. The reformed Exendin-4 is obtained by performing three site-directed mutations on natural Exendin-4, and the three site-directed mutations include: replacing asparagine at the 28th position with glutamine; eliminating a trypsin recognition site of Lys12-Arg13; and adding a cysteine residue at the C terminal. The engineering bacterium realizes high-efficiency secretory expression of the target protein based on a NICE induction system. The production system provided by the application has the advantages of food safety level, no anti-screening and simple process, and is suitable for development of an intestinal delivery system.

This invention belongs to the field of microbial technology, specifically relating to the application of *Lactococcus lactis* subsp. *milkfat* and its products in improving the effects of enteritis on weight, intestinal health, and immunity. This invention provides a novel *Lactococcus lactis* subsp. *milkfat* strain, with the preservation number CGMCC No. 29363. Experiments have shown that supplementation with *Lactococcus lactis* subsp. *milkfat* LC-99 can increase the weight of patients with enteritis, improve intestinal inflammatory symptoms, and enhance immune function.

This invention belongs to the field of microbial genetic engineering and metabolic engineering technology, specifically relating to decarboxylase mutants in the indolepyruvate pathway, their mutant combinations, and their application in the production of indoleacetic acid. A decarboxylase mutant was obtained by mutating glycine at position 255 of the indolepyruvate decarboxylase kivD derived from *Lactococcus lactis* to tyrosine, and serine at position 386 to glutamic acid. kivD G255Y / S386E The applicant expressed kivD freely in the engineered recombinant Bacillus licheniformis strain BLI-2. G255Y / S386E The strain BlI-3 was obtained, and the indoleacetic acid (IAA) yield of BlI-3 reached 675.6 mg / L, which was 70.09% higher than that of BlI-2 and 258.44% higher than that of BlI-1, significantly improving the level of IAA synthesis by the host strain.

This invention relates to a recombinant *Lactococcus lactis* microcapsule, its preparation method, and its applications, belonging to the field of genetic engineering. To address the technical problems of low safety, high side effects, unstable efficacy, and insufficient targeting in existing methods for treating or alleviating inflammatory bowel disease (IBD), this invention provides a recombinant *Lactococcus lactis* microcapsule. By integrating a fusion gene encoding catalase and superoxide dismutase, a recombinant *Lactococcus lactis* with antioxidant function is constructed. The recombinant *Lactococcus lactis* is then coated with a mucosa-adhesive chitosan and sodium alginate composite nanomaterial to obtain a microcapsule with antioxidant enzyme expression capabilities and a nano-protective coating. The recombinant *Lactococcus lactis* microcapsule provided by this invention can enhance the activity and bioavailability of orally delivered substances under the harsh acidic environment and complex physiological barriers of the gastrointestinal tract, providing a new strategy and experimental evidence for the clinical prevention and treatment of IBD.

The present invention relates to a Lactococcus lactis strain or a cell fraction thereof for use in the prevention and / or treatment of visceral pain.

The application discloses a fermentation method for high-yield hyaluronic acid, and belongs to the technical field of microbial fermentation. szhasABC The method adopts recombinant lactococcus carrying a gene cluster from streptococcus zooepidemicus as a production strain, externally adds leech-derived hyaluronidase in a fermentation process, and dynamically controls fermentation temperature (30-37 DEG C). The strategy ingeniously couples the biosynthesis of HA with controllable enzymolysis process, effectively releases the feedback inhibition of high-molecular-weight HA capsule on cell growth, and significantly improves the yield. Meanwhile, through accurate adjustment of process parameters, precise customization of product molecular weight is realized. Experimental results show that, by using the method, the yield of hyaluronic acid can reach 4.6 g / L at most, the molecular weight can be regulated in the range of 0.4 kDa to 850 kDa as required, and the deviation rate is less than 5%. The application does not need to perform complex gene editing on the host, does not depend on the preservation of specific engineering strains, has the advantages of high safety, simple process, low cost, strong controllability and the like, and is suitable for the large-scale production demand of different specifications of hyaluronic acid in the fields of food, cosmetics and medicine.

This invention relates to the field of biomedical genetic engineering, specifically to a *Lactococcus lactis* expression vector suitable for in vitro induction and its application. The expression vector utilizes the promoter and secretory signal peptide of the *Bifidobacterium* exoxylanase (ECX) gene to control the expression and secretion of exogenous genes. It can induce the expression and secretion of exogenous target genes in the intestinal lumen or in vitro using *Lactococcus lactis* as the host bacterium and xylooligosaccharides or xylans as inducers. By inserting the exogenous target gene into the *Lactococcus lactis* exogenous gene inducible expression vector of this invention, the host bacterium is electroporated to obtain genetically engineered bacteria, which can then be used to produce biopharmaceuticals or food products.

The present disclosure provides a use for preventing or treating chronic pain in a subject in need thereof, comprising administering to the subject an effective amount of Lactococcus lactis DSM 27109 composition.

The application discloses a kind of complex fermentation inoculant for improving equol production, fermentation liquor and application thereof, belong to microbial fermentation technical field.The complex fermentation inoculant of the application, streptococcus thermophilus BLCC2-0025 and lactococcus lactis MP1001 have high β-glucosidase activity, and low activity glycoside form is converted into high activity daidzein;Salivary lactobacillus LS1101 and lactobacillus gregius 0010 have the activity of further converting daidzein into equol;Four strains of bacteria are used in combination, which can synergistically improve the content of equol.The fermentation liquor prepared by fermenting pueraria extract with the complex fermentation inoculant of the application can target regulate intestine-ovary axis, significantly improve the reproductive function of POF mice, relieve ovarian oxidative stress and accurately regulate intestinal flora balance, providing a safe and effective preparation and application scheme for non-hormone intervention of premature ovarian failure.

The invention discloses functional probiotics for relieving nutrition metabolism disorder of aquatic animals and application of the functional probiotics, and relates to the technical field of aquaculture, the functional probiotics are Lactococcus lactis GCL-1, the Lactococcus lactis GCL-1 is preserved in the China General Microbiological Culture Collection Center on January 7, 2026, and the preservation number is CGMCC NO.37318. The invention further discloses a preparation method of the functional probiotics for relieving the nutrition metabolism disorder of the aquatic animals and application of the functional probiotics for relieving the nutrition metabolism disorder of the aquatic animals. After the lactococcus lactis GCL-1 provided by the invention is applied to an aquatic animal feed, the growth performance of the aquatic animal can be improved, liver oxidative stress, inflammation and lipid metabolism disorder induced by a high cottonseed meal feed can be relieved, meanwhile, the intestinal health is improved, and the physiological health of the aquatic animal is improved.

The application belongs to the technical field of biological pharmacy, and discloses a recombinant lactococcus lactis live carrier vaccine, which is obtained by connecting a urease subunit UreA gene with a plasmid expression vector and then electrically transforming the lactococcus lactis; the amino acid sequence of the urease subunit UreA gene is shown as SEQ ID NO. 1. The application further discloses application of the recombinant lactococcus lactis live carrier vaccine in preparation of an anti-helicobacter pylori vaccine. The recombinant lactococcus lactis live carrier vaccine provided by the application can effectively stimulate the body to produce a mucosal immune response and has good protection effect.